The role of Human Leukocyte Antigen (HLA) alleles in colorectal cancer susceptibility, development and progression is the focus of ongoing scrutiny. MHC polymorphisms in a Sudanese family with hereditary colorectal cancer were studied using an in silico approach and the results were verified using The Cancer Genome Atlas (TCGA). In this family study, we tested for sharing of nucleotide polymorphisms identified by whole exome capture in major histocompatibility complex region and carried out in-silico prediction of their effects in tumor and control samples. SNPs were analyzed to highlight identical by state sharing, to identify runs of homozygosity, as well as to predict structural and functional effects using homology modeling, damaging effect predictions, and regulatory changes prediction.
INTRODUCTION
Colorectal tumors range from benign growths to invasive cancer and are predominantly epithelial-derived tumors (i.e., adenomas or adenocarcinomas). Colorectal carcinoma (CRC) is a leading cause of death in the world. Genome-wide analysis of gene mutations in CRC has identified acquired somatic mutations in several genes, highlighting the heterogeneity of the disease. In addition, each tumor usually shows a distinct mutational gene signature [1, 2] . A portion of colorectal cancers display microsatellite instability [MSI; 15% of CRCs) characterized by defective DNA mismatch repair (MMR) system [3, 4] . Genetic susceptibility to colorectal cancer is described primarily in familial colorectal cancer syndromes like hereditary nonpolyposis colorectal cancer (HNPCC). Notably, none of CRC susceptibility genetic polymorphisms were found in the major histocompatibility complex (MHC) region located in chromosome 6 (6p21. 3) , which is one of the most polymorphic areas in the human genome. It has been argued that human leukocyte antigens (HLA) polymorphisms can explain much of the diversity in cancer predisposition, progression and prognosis.
The loss of HLA gene expression owing to viral infection, somatic mutations or other causes may have important effects on immune suppression and cancer development . It is well known that some infection-related malignancies (e.g. Epstein-Barr virus, Human Papilloma Virus) show HLA-related predisposition or protection. Bernel-Silva et al. found that HLA-DRB1*14 allele seems to confer protection against cervical cancer [5] . However, other types of cancer with no clear relation to infectious agents show HLA predisposition as well. Although large genome-wide association studies have failed to demonstrate association between colorectal cancer and HLA SNPs, a previous study reported that HLA-DQA1* 0201 was significantly less common in patients with colonic carcinoma than controls [6] . HLA DQB*03032 and HLA DRB1*11 alleles may have a protective role in human breast cancer. HLA DRB1*11 alleles were found significantly overrepresented (P<0.0001) in controls as compared with patients with early-onset breast cancer [7] . HLA DRB1*0901 allele was found to be more prevalent in the patients of esophageal carcinoma compared to healthy controls in Hubei Han Chinese, possibly indicating higher susceptibility [8] . El-chennawi et al. found a significantly increased frequency of HLA-DRB1*04, DRB1*07, and DQB1*02 in Hepato-Cellular Carcinoma Egyptian patients versus control group, as well as a significantly decreased frequency of DQB1*06 and DRB1*15 [9] . It was shown that somatic mutations in cancer can affect the binding groove of HLA genes, possibly altering the binding specificities of these molecules. Variants showing potential epigenetic, peptide-loading function and T-cell immune response were correlated with the effects of HLA-A*11:01, a protective HLA-A allele against nasopharingeal carcinoma in Malaysian Chinese population. Most other HLA-A variants did not appear to possess any potential function [10] .
This study aimed to characterize MHC SNPs in HNPCC by analyzing MHC polymorphisms in a Sudanese family with hereditary colorectal cancer. Analysis of exomes of tumor and control samples from this family showed an interesting shared mutation pattern in tumor samples as described by Suleiman et al. [11] . In this study, we focused on MHC genes and found features of identical by state SNP sharing affecting HLA-DQ binding groove and thus the binding specificity.
METHODS

Study Materials and Exome Sequencing:
The study examined exome sequences from an extended Sudanese family with a history of hereditary colorectal cancer previously described by Suleiman et al. [11] . We took two cancer patients and two related controls. DNA was extracted using standard techniques from tumor samples obtained following surgical resection from the two cancer patients and control blood samples from two controls (a sister to one patient and another distant cousin from a branch of the extended family) . Quality of extracted DNA was assured and whole exome sequencing was performed (BGI©, China) on Illumina HiSeq2000 platform (Illumina, USA) . Alignment was performed using BWA [12] . SNP discovery and genotype calling was done using SOAPsnp [13] . INDEL calling was performed using ATLAS2 [14] . This study utilized the results of called SNPs in MHC area on chromosome 6 by filtering MHC genes from the total variant calls.
Variants Analysis: SNPs found in the MHC region in study samples were studied in terms of reported association to cancer, amount of variant sharing, homozygosity and variants effect prediction. SNPs number, sharing, identity, heterozygozity, predicted structural/functional outcomes of observed variants, possible effect on regulatory sites, as well as haplotype sharing was studied using In-Silico tools and databases as detailed below.
Annotation and Effect Prediction:
The identified SNPs were annotated using SNPNexus tool [15] .
Variants were tested for possible Transcription Factor Binding Sites (TFBS), miRNA binding using 3 60 65 70 75 80 SNPNexus. Genomic Evolutionary Rate Profiling (GERP++) conservation scores [16] were used to assess if mutations affected conserved sequences of genome. Relation of SNPs to Sequence Feature Variant Types sites (SFVTs) were checked using definitions on NCBI protein database. NCBI Genetic Association Database [17] and Phenotype-Genotype Integrator [18] were searched for reported SNPs in our samples. Damaging effects of non-synonymous coding variants were predicted using Consensus Deleteriousness (ConDel) scores [19] . iMutant2 [20] was used to predict changes in protein stability caused by single mutations with high probability of damaging effect reflected in predicted free energy change (DDG) scores. Swiss-Model [21] was used to predict the 3D structure of mutated HLA proteins using reference UniProtKB sequences. UCSF Chimera [22] was used to visualize modeled PDB files.
Regulatory effects of SNPs were assessed using multiple tools: RegulomeDB scores [23] , Alibaba 2.1 [24] and TFSEARCH [24] .
Marker sharing: Beagle/fastIBD [25] software package was used for Identity By Descent (IBD) and
Homozygosity By Descent (HBD) inference. Significance of marker sharing was tested by Chi-square test at 1000 Monte Carlo permutations using Haploview [26] . Mantel statistic was used to test haplotype sharing among individuals using Step-down adjusted p-values (adjusting for the Family Wise Error Rate) calculated at 1000 Monte Carlo Permutations using the software Tomcat v1.0 [27] . (3)). All were located in close proximity to the binding groove. On the other hand, All SNPs seen in controls (whether exclusively or shared with tumors) were found to be located relatively distant from the binding groove of HLA-DQB1.
Two coding SNPs were predicted to be deleterious on protein structure using ConDel. An HLA-A polymorphism resulting in G80R amino acid change (rs1059449) was predicted to be deleterious on two transcripts (2 and 201) of the HLA-A gene (gene has 10 transcripts). iMutant predicted decreased stability (DDG score -0.52; SNP largely destabilize the protein if DDG<-0.5 Kcal/mol). It was found as a homozygous polymorphism in tumor sample P61. Another polymorphism in HLA-DQA1 gene (rs10093) was predicted to be deleterious resulting in a Q30E amino acid change in gene transcript 008 (gene has 10 transcripts). iMutant predicted weak effect on protein stability (DDG scores of -0.09; SNP has a weak effect if -0.5<DDG<0.5). p300 that is affected by rs1063318 but with a slight change in score. On the contrary, Alibaba did not predict a p300 binding site. RegulomeDB scores showed only three variants (rs12363, rs1049053, and rs1064594) with relatively high score, all mapped to controls. No variants were predicted to affect miRNA binding.
DISCUSSION
The role of MHC in colorectal cancer is not well understood. HLA variants have been linked to many types of malignancies including cervical, lung, breast and other malignancies [5] [6] [7] [8] [9] .
However, a search for phenotypic association of SNPs seen in this study with colorectal cancer did not return a previously reported association. In fact, only a small number of studies, if any, have shown a relation between HLA alleles and CRC risk. A previous study reported that HLA-DQA1* 0201 was less common in 80 Italian patients with colonic carcinoma than controls (8% vs. 18%, P-value with Bonferroni correction = 0.027; OR = 0.44) [6] . Nonetheless, antigen presentation pathway was found to be central in colorectal cancer pathogenesis and showed enrichment in relapsed tumors [30] . Systems Biology analysis also featured a central role for HLA proteins [30] . In this study, identical by state sharing of HLA SNPs between tumor samples in HLA-DQB1 was noted (figure (2)).
High degree of homozygosity was seen in tumor samples in MHC II area ( figure (1) ). This Run of Homozygosity seen in the MHC II is likely to represent Loss of Heterozygosity (LOH). Runs of Homozygosity (ROH) are not unusual in cancer genomes and in colorectal cancer specifically.
Ozaslan and Aytekin have shown LOH in colorectal cancer genomes at multiple chromosomes [31] . Generally, ROH might indicate copy-neutral loss of heterozygosity or copy number variation and subsequent haploinsufficiency. In fact, haploinsufficiency was found to drive aneuploidy patterns and shape the cancer genome. The vast majority of sporadic tumor suppressors are likely to be haploinsufficient [32] . High-frequency LOH was also found to correlate with high metastatic potential of colorectal cancers [33] . These events seem to be somatic in origin. Siraj et al. studied the genome homozygosity in Saudi consanguineous families with CRC family history and concluded that there is no correlation between autozygosity in germline genome and CRC risk [28] . Interestingly, studies did not report LOH at MHC region on chromosome 6p. Although LOH is a common phenomenon in a variety of human cancers, a high frequency allelic loss at a specific chromosomal region indicates the location of a candidate tumor suppressor gene and micro-deletions. In this study it's premature to conclude the presence of a tumor suppressor locus based on current data alone without considering the frequency of heterozygosity loss. Yet, such a high degree of homozygosity points to this possibility. The increased homozygosity was not seen in control samples.
The central feature of HLA proteins in biological processes remains their ability to recognize and bind peptides. The binding specificity of HLA molecules is basically determined by variations in the surface of the binding groove. The fact that all the non-synonymous coding variants seen exclusively in tumor samples here are in close proximity to the binding groove of HLA-DQB1 emphasizes an active role for the observed haplotype in colorectal cancer pathogenesis (in fact three of them were localized on the surface of the binding groove; figure (3) ). This spatial position of shared variants was unique to tumor samples: all the shared variants in controls were distant from the binding groove.
In this study, the observation that SNPs seen in MHC II area are not predicted to be damaging (to most of transcripts) possibly relates to an active role for MHC in CRC pathogenesis and negative selection of damaging variants, making completely detrimental variants an unlikely occurrence.
This role is unlikely to be mediated by a damaging effect on protein structure as we argued. For surface MHC I, cells failing to express MHC I induce immune response, at least in early tumor transformation, targeted to eliminate such cells for example by Natural Killer cells [34] . In this sense, immune-editing in colorectal cancer is thought to occur at level of expression of classic and non-classic HLA genes as shown by some studies [35] . However, stable class II MHC is constitutively expressed only in Antigen Presenting Cells surface. Almost all normal gastrointestinal epithelial cells lack surface MHC class II. Gastrointestinal cancer cells often do not express MHC class II molecules, which are associated with T-cell-mediated anti-tumor immune responses [36, 37] . Several reports suggest that forced expression of MHC in cancer cells leads to loss of tumorigenicity [38] . Non-viral tumors frequently lose expression of HLA molecules such as the reduction or total loss in colorectal carcinoma [39] . This raises another question on how do these observed variants in MHC II participates in cancer pathogenesis. They are more likely to represent a tumor-selected haplotype that participates in pathogenesis and immune response to cancer. How this can be achieved is likely beyond a classical explanation of surface expression of MHC, especially when we consider the lack of inducible surface 8 expression of MHC II in malignancies. One possibility is that the role of MHC II expression in CRC relates to exosomes and extracellualr vesicle transport. Exosomes are rich in MHC II proteins and have been demonstrated to carry certain markers in cancer [40] . They are also demonstrated to induce tolerance by communication with the dendritic and T-cells in many models. It is plausible as well that exosomes bearing antigen/MHC complexes transmit death signals that cause specific killing of the T cell clones that pose a threat to the exosome-producing cell [41, 42] .
CONCLUSION
In this family study, an in-silico analysis was carried out on the results of whole exome capture of two colorectal cancer tumor samples and two control blood samples from healthy related individuals. MHC II area showed high degree of homozygosity in tumor samples evidenced by the presence of runs of homozygosity. This might represent a possibility of disease predisposing or a tumor suppressor locus affected by neoplastic transformation. Shared markers were found non-identical by descent. No marker or haplotype sharing was proved statistically significant using non-parametric tests of significance, but this might be explained by the rather small number of studied samples. Sharing of three exonic non-synonymous variants was seen between tumor samples. Tumor-shared SNPs, unlike those of controls, were predicted to affect the binding groove of HLA-DQB1 protein and thus affect its binding specificity. The results demonstrate IBS SNP sharing and possible loss of heterozygosity in classic MHC II region in cancer tissues. The significance of this sharing is yet to be determined. Changes in binding specificity and extracellualr transport seem to be plausible explanations for HLA role in this study.
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